<?xml version="1.0" encoding="utf-8"?> <feed xmlns:dc="http://dublincore.org/documents/dcmi-namespace/" xmlns:media="http://search.yahoo.com/mrss/" xmlns="http://www.w3.org/2005/Atom"> <title type="text">Corbus Pharmaceuticals Holdings, Inc.</title> <subtitle type="text">Contains the last 20 releases</subtitle> <id>uuid:050372ea-4a34-402c-afa0-58ce5a4baa65;id=49183</id> <rights type="text">Copyright 2024, Corbus Pharmaceuticals Holdings, Inc.</rights> <updated>2024-11-12T13:00:00Z</updated> <author> <name>newsdesk@globenewswire.com (NewsDesk)</name> <uri>http://www.globenewswire.com/LegacyRss?Length=4</uri> <email>newsdesk@globenewswire.com</email> </author> <link rel="alternate" href="https://www.globenewswire.com/atomfeed/organization/qZco2tdJ3TziCZaZocpWsw==" /> <link rel="self" href="https://www.globenewswire.com/atomfeed/organization/qZco2tdJ3TziCZaZocpWsw==" /> <entry> <id>https://www.globenewswire.com/news-release/2024/11/12/2979102/0/en/Corbus-Pharmaceuticals-to-Present-at-the-Jefferies-London-Healthcare-Conference.html</id> <title type="text">Corbus Pharmaceuticals to Present at the Jefferies London Healthcare Conference</title> <published>2024-11-12T13:00:00Z</published> <updated>2024-11-13T18:48:28Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/11/12/2979102/0/en/Corbus-Pharmaceuticals-to-Present-at-the-Jefferies-London-Healthcare-Conference.html" /> <category term="Nasdaq:CRBP" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US21833P3010" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="left">NORWOOD, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and one-on-one investor meetings at the Jefferies London Healthcare Conference to be held November 19-21, 2024 in London, UK.</p>]]></content> <dc:identifier>2979102</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Corbus Pharmaceuticals Holdings, Inc.</dc:contributor> <dc:modified>Tue, 12 Nov 2024 13:02 GMT</dc:modified> <dc:subject>Health</dc:subject> <dc:subject>Conference Calls/ Webcasts</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/11/07/2976498/0/en/Corbus-Pharmaceuticals-Reports-3rd-Quarter-2024-Financial-Results-and-Provides-a-Corporate-Update.html</id> <title type="text">Corbus Pharmaceuticals Reports 3rd Quarter 2024 Financial Results and Provides a Corporate Update</title> <published>2024-11-07T12:00:00Z</published> <updated>2024-11-13T18:48:28Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/11/07/2976498/0/en/Corbus-Pharmaceuticals-Reports-3rd-Quarter-2024-Financial-Results-and-Provides-a-Corporate-Update.html" /> <category term="Nasdaq:CRBP" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US21833P3010" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">NORWOOD, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, today provided a corporate update and reported financial results for the quarter ended September 30, 2024.</p>]]></content> <dc:identifier>2976498</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Corbus Pharmaceuticals Holdings, Inc.</dc:contributor> <dc:modified>Thu, 07 Nov 2024 12:01 GMT</dc:modified> <dc:subject>Earnings Releases and Operating Results</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/11/04/2973892/0/en/Corbus-Pharmaceuticals-Presents-New-CRB-913-Pre-Clinical-Data-At-Obesity-Week-2024.html</id> <title type="text">Corbus Pharmaceuticals Presents New CRB-913 Pre-Clinical Data At Obesity Week 2024</title> <published>2024-11-04T12:00:00Z</published> <updated>2024-11-13T18:48:28Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/11/04/2973892/0/en/Corbus-Pharmaceuticals-Presents-New-CRB-913-Pre-Clinical-Data-At-Obesity-Week-2024.html" /> <category term="Nasdaq:CRBP" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US21833P3010" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">NORWOOD, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, presents new pre-clinical data at Obesity Week 2024 further characterizing CRB-913, its highly peripherally restricted CB1 inverse agonist. The data are being presented as a <a href="https://www.globenewswire.com/Tracker?data=uHUgY9lq4OdNgFKQDnOSUERY80ul9aQbcQ2zcd9QwWO10DmvZ2ry_Oj0kZY8XKow8LiwkPHY-d4jr8aw7jgYnzuy6gts1PeCu4oUHVpCAAg9C4M8wyBIYNaq-tj1g873rV8Zvzql53RUa3ocAYOf-BOc3eH3SyCG47smMnQMveAZQV8Z-e5jF8fBXwqOegNrfS6N23RJS2dQimjiofNNO5Hd32ghUXpcwNLbPDqyaYE169ub9oll_M7VzPu74lUwGuDmhGmioDIIEMdzaNT4fFOpJvXAn3wWHzoeT4tDlwE7no3yHFMQY_M3Sh-XVl-lcTDQ8yrSXMX2mWHYK3sH0gM8BEt1XBnU5Zfnr3i4mBXgUni4DcMCK4sIQ6KbSIRM" rel="nofollow" target="_blank" title="Poster Presentation">Poster Presentation</a> titled: “Induction and Maintenance Regimens with CB1 Inverse Agonist CRB-913 and Semaglutide in DIO Mice”.</p>]]></content> <dc:identifier>2973892</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Corbus Pharmaceuticals Holdings, Inc.</dc:contributor> <dc:modified>Mon, 04 Nov 2024 12:00 GMT</dc:modified> <dc:subject>Clinical Study</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/10/29/2970738/0/en/Corbus-Pharmaceuticals-to-Present-at-the-Guggenheim-Securities-Healthcare-Innovation-Conference.html</id> <title type="text">Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference</title> <published>2024-10-29T12:00:00Z</published> <updated>2024-11-13T18:48:28Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/10/29/2970738/0/en/Corbus-Pharmaceuticals-to-Present-at-the-Guggenheim-Securities-Healthcare-Innovation-Conference.html" /> <category term="Nasdaq:CRBP" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US21833P3010" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="left">NORWOOD, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and one-on-one investor meetings at the Guggenheim Securities Healthcare Innovation Conference to be held November 11-13, 2024 in Boston, MA.</p>]]></content> <dc:identifier>2970738</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Corbus Pharmaceuticals Holdings, Inc.</dc:contributor> <dc:modified>Tue, 29 Oct 2024 12:00 GMT</dc:modified> <dc:subject>Calendar of Events</dc:subject> <dc:subject>Conference Calls/ Webcasts</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/10/16/2963983/0/en/Corbus-Announces-Enrollment-Completion-of-Dose-Escalation-Stage-of-Phase-1-Clinical-Trial-of-Its-Next-Generation-Nectin-4-Targeting-ADC-CRB-701.html</id> <title type="text">Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)</title> <published>2024-10-16T12:00:00Z</published> <updated>2024-11-13T18:48:28Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/10/16/2963983/0/en/Corbus-Announces-Enrollment-Completion-of-Dose-Escalation-Stage-of-Phase-1-Clinical-Trial-of-Its-Next-Generation-Nectin-4-Targeting-ADC-CRB-701.html" /> <category term="Nasdaq:CRBP" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US21833P3010" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">NORWOOD, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, announced today that it has completed enrollment of the dose escalation part of its bridging Phase 1 clinical trial of CRB-701 (SYS6002). The dose escalation part of this open label study <a href="https://www.globenewswire.com/Tracker?data=Nn5ml121nuuB4iVxNUo7bRE6ZTXxsX9wbXEy0KqOBTgYoMtn9TpraXhp5reHRojQRyYT_I7bAPvtzl-4N5s_cxHTEEQ41uBenUfha921SH1o8FfgLs0Rb9NtUEo-Jqq-Djyt6DrKLsIBMD-6NsQk_w==" rel="nofollow" target="_blank" title="(NCT06265727)">(NCT06265727)</a> is being conducted in the US and the UK. The three-part Phase 1 trial is evaluating the safety, pharmacokinetics and efficacy of CRB-701 in patients with advanced solid tumors associated with high Nectin-4 expression. The Part A dose escalation of the Phase 1 study is evaluating four predetermined doses (1.8 mg/kg, 2.7 mg/kg, 3.6 mg/kg and 4.5 mg/kg) and will be followed by Part B (dose optimization) and Part C (dose expansion) that will determine recommended/optimized doses and seek preliminary efficacy signals.<br></p>]]></content> <dc:identifier>2963983</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Corbus Pharmaceuticals Holdings, Inc.</dc:contributor> <dc:modified>Wed, 16 Oct 2024 12:00 GMT</dc:modified> <dc:subject>Clinical Study</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/09/26/2953734/0/en/Corbus-Pharmaceuticals-to-Participate-in-the-BMO-Capital-Markets-Oncology-Summit.html</id> <title type="text">Corbus Pharmaceuticals to Participate in the BMO Capital Markets’ Oncology Summit</title> <published>2024-09-26T12:00:00Z</published> <updated>2024-11-13T18:48:28Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/09/26/2953734/0/en/Corbus-Pharmaceuticals-to-Participate-in-the-BMO-Capital-Markets-Oncology-Summit.html" /> <category term="Nasdaq:CRBP" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US21833P3010" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">NORWOOD, Mass., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that the Company will participate in <em>BMO Capital Markets’ Oncology Summit</em>, to be held October 8, 2024 in New York, NY. Dr. Dominic Smethurst, MA MRCP, Chief Medical Officer of Corbus, will participate in a panel titled <em>Capitalizing on Validated Mechanism in Oncology</em>. Dr. Smethurst will also be joined by Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, to participate in one-on-one investor meetings.<br></p>]]></content> <dc:identifier>2953734</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Corbus Pharmaceuticals Holdings, Inc.</dc:contributor> <dc:modified>Thu, 26 Sep 2024 12:00 GMT</dc:modified> <dc:subject>Calendar of Events</dc:subject> <dc:subject>Conference Calls/ Webcasts</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/09/05/2941312/0/en/Corbus-Pharmaceuticals-to-Present-at-the-2024-Cantor-Global-Health-Conference.html</id> <title type="text">Corbus Pharmaceuticals to Present at the 2024 Cantor Global Health Conference</title> <published>2024-09-05T12:00:00Z</published> <updated>2024-11-13T18:48:28Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/09/05/2941312/0/en/Corbus-Pharmaceuticals-to-Present-at-the-2024-Cantor-Global-Health-Conference.html" /> <category term="Nasdaq:CRBP" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US21833P3010" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">NORWOOD, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present at the <em>2024 Cantor Global Health Conference</em>, to be held September 17-19, 2024 in New York, NY. Dr. Cohen will participate in a fireside chat with Cantor analyst Prakhar Agrawal and participate in one-on-one investor meetings.<br></p>]]></content> <dc:identifier>2941312</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Corbus Pharmaceuticals Holdings, Inc.</dc:contributor> <dc:modified>Thu, 05 Sep 2024 12:01 GMT</dc:modified> <dc:subject>Calendar of Events</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/08/20/2932731/0/en/Corbus-Pharmaceuticals-Strengthens-Board-of-Directors-with-Appointment-of-Winston-Kung.html</id> <title type="text">Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung</title> <published>2024-08-20T12:00:00Z</published> <updated>2024-11-13T18:48:28Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/08/20/2932731/0/en/Corbus-Pharmaceuticals-Strengthens-Board-of-Directors-with-Appointment-of-Winston-Kung.html" /> <category term="Nasdaq:CRBP" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US21833P3010" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">NORWOOD, Mass., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced the appointment of Winston Kung to its Board of Directors. The appointment was effective as of August 16, 2024. Mr. Kung will also chair the Audit Committee.<br></p>]]></content> <dc:identifier>2932731</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Corbus Pharmaceuticals Holdings, Inc.</dc:contributor> <dc:modified>Tue, 20 Aug 2024 12:00 GMT</dc:modified> <dc:subject>Directors and Officers</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/08/06/2924986/0/en/Corbus-Pharmaceuticals-Reports-Second-Quarter-2024-Financial-Results-and-Provides-a-Corporate-Update.html</id> <title type="text">Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update</title> <published>2024-08-06T12:00:00Z</published> <updated>2024-11-13T18:48:28Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/08/06/2924986/0/en/Corbus-Pharmaceuticals-Reports-Second-Quarter-2024-Financial-Results-and-Provides-a-Corporate-Update.html" /> <category term="Nasdaq:CRBP" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US21833P3010" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">NORWOOD, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today provided a corporate update and reported financial results for the quarter ended June 30, 2024.</p>]]></content> <dc:identifier>2924986</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Corbus Pharmaceuticals Holdings, Inc.</dc:contributor> <dc:modified>Tue, 06 Aug 2024 12:00 GMT</dc:modified> <dc:subject>Earnings Releases and Operating Results</dc:subject> <dc:subject>Health</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/07/30/2921022/0/en/Corbus-Pharmaceuticals-to-Participate-in-Upcoming-Investor-Conferences-in-August.html</id> <title type="text">Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in August</title> <published>2024-07-30T12:50:40Z</published> <updated>2024-11-13T18:48:28Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/07/30/2921022/0/en/Corbus-Pharmaceuticals-to-Participate-in-Upcoming-Investor-Conferences-in-August.html" /> <category term="Nasdaq:CRBP" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US21833P3010" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">NORWOOD, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in two investor conferences during the month of August. Dr. Cohen will provide a corporate update and participate in one-on-one investor meetings at the following events.<br></p>]]></content> <dc:identifier>2921022</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Corbus Pharmaceuticals Holdings, Inc.</dc:contributor> <dc:modified>Tue, 30 Jul 2024 12:50 GMT</dc:modified> <dc:subject>Calendar of Events</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/06/01/2891822/0/en/SYS6002-CRB-701-A-Next-Generation-Nectin-4-Targeting-Antibody-Drug-Conjugate-Continues-to-Demonstrate-Encouraging-Safety-and-Efficacy-Observed-in-Patients-with-Nectin-4-Positive-Tu.html</id> <title type="text">SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024</title> <published>2024-06-01T14:00:00Z</published> <updated>2024-11-13T18:48:28Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/06/01/2891822/0/en/SYS6002-CRB-701-A-Next-Generation-Nectin-4-Targeting-Antibody-Drug-Conjugate-Continues-to-Demonstrate-Encouraging-Safety-and-Efficacy-Observed-in-Patients-with-Nectin-4-Positive-Tu.html" /> <category term="Nasdaq:CRBP" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US21833P3010" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">NORWOOD, Mass., June 01, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), announced today, that the Poster [#296] <a href="https://www.globenewswire.com/Tracker?data=6gdTy0yxm8xXnekz5RJpF_paOcRmE1pbd2A82U-ZdHjX6zWKv7q4-DIHLofTqL1nhRTYCkJ238wemUVhHQXvR9MnEMdE-p_uqQz0SavqBVAOfT_y8Js5BReX5DsFhWF1ZM8D15txSVYmG4kSK5KWBKHkcdOXjQbZzr0hGsq7LS3KLV-WbALCEOBJd2hfXNgkUsL10VCc6BxpOZMGodIJRprSebdqS3Lq230rV-S6BVON1PrnhhHP0XMzX9oebR8ICTphEAfoPKT06XXk6ThqpQ==" rel="nofollow" target="_blank" title=""><em><u>Clinical Update Related to the First-In-Human Trial of SYS6002 (CRB-701), A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate</u></em></a>, has been presented at American Society of Clinical Oncology (ASCO) Annual Conference by Dr. Jian Zhang, Chief Physician (Oncology), Deputy Director of Administration, Clinical director of Phase 1 Centre, Fudan University Shanghai Cancer Center.</p>]]></content> <dc:identifier>2891822</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Corbus Pharmaceuticals Holdings, Inc.</dc:contributor> <dc:modified>Sat, 01 Jun 2024 14:00 GMT</dc:modified> <dc:subject>Product / Services Announcement</dc:subject> <dc:subject>Clinical Study</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/05/30/2890710/0/en/Corbus-Pharmaceuticals-to-Present-at-the-45th-Annual-Goldman-Sachs-Global-Healthcare-Conference.html</id> <title type="text">Corbus Pharmaceuticals to Present at the 45th Annual Goldman Sachs Global Healthcare Conference</title> <published>2024-05-30T12:00:00Z</published> <updated>2024-11-13T18:48:28Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/05/30/2890710/0/en/Corbus-Pharmaceuticals-to-Present-at-the-45th-Annual-Goldman-Sachs-Global-Healthcare-Conference.html" /> <category term="Nasdaq:CRBP" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US21833P3010" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">NORWOOD, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will provide a corporate update and participate in one-on-one investor meetings at the 45<sup>th</sup> Annual Goldman Sachs Global Healthcare Conference to be held June 10-13, 2024 in Miami Beach, FL.<br></p>]]></content> <dc:identifier>2890710</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Corbus Pharmaceuticals Holdings, Inc.</dc:contributor> <dc:modified>Thu, 30 May 2024 12:01 GMT</dc:modified> <dc:subject>Conference Calls/ Webcasts</dc:subject> <dc:subject>Calendar of Events</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/05/23/2887706/0/en/Updated-Phase-1-Clinical-Data-for-SYS-6002-CRB-701-to-be-presented-at-2024-ASCO-Annual-Meeting.html</id> <title type="text">Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting</title> <published>2024-05-23T21:05:26Z</published> <updated>2024-11-13T18:48:28Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/05/23/2887706/0/en/Updated-Phase-1-Clinical-Data-for-SYS-6002-CRB-701-to-be-presented-at-2024-ASCO-Annual-Meeting.html" /> <category term="Nasdaq:CRBP" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US21833P3010" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">NORWOOD, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) announced today that the abstract [No. 3151] for a poster presentation at the <em>2024 American Society of Clinical Oncology </em>(ASCO) annual meeting being held from May 31-June 4, 2024 in Chicago has been released. The ASCO abstract is titled: <a href="https://www.globenewswire.com/Tracker?data=tZ6ftS9LlXhc-qnTXh3XaHkKnEMl4AF9U-ZAA3Bi3026kk-PyIhTXp1wItWYOaDkxZko279j9AyLUT9q5o2XN6xHK4H-NjlnmKRyEpn5MrPR2yQCDlt8y9mDWElGLaLm_YPwjEegsXPtCjXBBGb3CUXJJHyrfhhciSR6GnlpkQ76wcx7dIDczkUUYJw0nOY69z-ezhs75C1slaP7-tHdETuZlhBqCRQTuwH5b1B1t17AkCaGwHbDyj_u79l1_y4zWEi_mboFKtG4JVEZOJ6EBZSqG1ZHogaIhX-2WFUekInkEfU-9U_kUlH8Xa72GUDGuvx8Ya9s5Hi8LkRaUseAug==" rel="nofollow" target="_blank" title=""><em>Clinical Update Related to the First-In-Human Trial of SYS6002 (CRB-701), A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate</em></a> and will be presented as a poster [#296] on June 1, 2024 from 9:00 AM -12:00 PM by Dr. Jian Zhang, Fudan University Shanghai Cancer Center.<br></p>]]></content> <dc:identifier>2887706</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Corbus Pharmaceuticals Holdings, Inc.</dc:contributor> <dc:modified>Thu, 23 May 2024 21:05 GMT</dc:modified> <dc:subject>Annual Meetings & Shareholder Rights</dc:subject> <dc:subject>Calendar of Events</dc:subject> <dc:subject>Clinical Study</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/05/09/2878701/0/en/Corbus-Pharmaceuticals-to-Participate-in-the-2024-RBC-Capital-Markets-Global-Healthcare-Conference.html</id> <title type="text">Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference</title> <published>2024-05-09T12:00:00Z</published> <updated>2024-11-13T18:48:28Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/05/09/2878701/0/en/Corbus-Pharmaceuticals-to-Participate-in-the-2024-RBC-Capital-Markets-Global-Healthcare-Conference.html" /> <category term="Nasdaq:CRBP" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US21833P3010" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="left">NORWOOD, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and one-on-one investor meetings at the 2024 RBC Capital Markets Global Healthcare Conference to be held May 14-15, 2024 in New York, NY.<br></p>]]></content> <dc:identifier>2878701</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Corbus Pharmaceuticals Holdings, Inc.</dc:contributor> <dc:modified>Thu, 09 May 2024 12:01 GMT</dc:modified> <dc:subject>Calendar of Events</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/05/07/2876677/0/en/Corbus-Pharmaceuticals-Reports-First-Quarter-2024-Financial-Results-and-Provides-Corporate-Update.html</id> <title type="text">Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update</title> <published>2024-05-07T12:00:00Z</published> <updated>2024-11-13T18:48:28Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/05/07/2876677/0/en/Corbus-Pharmaceuticals-Reports-First-Quarter-2024-Financial-Results-and-Provides-Corporate-Update.html" /> <category term="Nasdaq:CRBP" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US21833P3010" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">NORWOOD, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today provided a corporate update and reported financial results for the quarter ended March 31, 2024.</p>]]></content> <dc:identifier>2876677</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Corbus Pharmaceuticals Holdings, Inc.</dc:contributor> <dc:modified>Tue, 07 May 2024 12:00 GMT</dc:modified> <dc:subject>Earnings Releases and Operating Results</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/05/01/2873204/0/en/Corbus-Pharmaceuticals-to-Participate-in-the-BTIG-Obesity-Health-Forum.html</id> <title type="text">Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum</title> <published>2024-05-01T12:00:00Z</published> <updated>2024-11-13T18:48:28Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/05/01/2873204/0/en/Corbus-Pharmaceuticals-to-Participate-in-the-BTIG-Obesity-Health-Forum.html" /> <category term="Nasdaq:CRBP" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US21833P3010" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">NORWOOD, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a panel discussion as part of the <em>BTIG Obesity Health Forum,</em> to be held virtually on May 8, 2024.</p>]]></content> <dc:identifier>2873204</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Corbus Pharmaceuticals Holdings, Inc.</dc:contributor> <dc:modified>Wed, 01 May 2024 12:01 GMT</dc:modified> <dc:subject>Calendar of Events</dc:subject> <dc:subject>Health</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/04/24/2869070/0/en/Corbus-Pharmaceuticals-Announces-Abstract-Accepted-for-Presentation-at-2024-ASCO-Annual-Meeting.html</id> <title type="text">Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting</title> <published>2024-04-24T20:05:00Z</published> <updated>2024-11-13T18:48:28Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/04/24/2869070/0/en/Corbus-Pharmaceuticals-Announces-Abstract-Accepted-for-Presentation-at-2024-ASCO-Annual-Meeting.html" /> <category term="Nasdaq:CRBP" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US21833P3010" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">NORWOOD, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that an abstract providing updated data from the Phase 1, first-in-human clinical data from a dose escalation study being carried out by its partner CSPC in China with CRB-701 (SYS6002) has been accepted for presentation at <em>the </em><a href="https://www.globenewswire.com/Tracker?data=NVKOQBFE6O1sWb0oXd3SwW19vI29dP5TE2SOPZtx-GF1Cxxnvsi4-QlaI3r3vKBCFPU5BvnY2_9qp3Cdwjx_JCQssA9EJFhUZ_Sz6xoGosRoPk-QXh2e-cOFwYOGp-J7" rel="nofollow" target="_blank" title=""><em>2024 American Society of Clinical Oncology</em></a> annual meeting, to be held May 31-June 4, 2024 in Chicago, IL. CRB-701 (SYS6002) is a next-generation antibody-drug-conjugate (ADC) targeting Nectin-4 with a third generation, site-specific cleavable linker and a homogenous drug antibody ratio of 2, using MMAE as the payload. Encouraging safety and efficacy data from this trial were presented at ASCO-GU 2024.<br></p>]]></content> <dc:identifier>2869070</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Corbus Pharmaceuticals Holdings, Inc.</dc:contributor> <dc:modified>Wed, 24 Apr 2024 20:05 GMT</dc:modified> <dc:subject>Calendar of Events</dc:subject> <dc:subject>Health</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/04/02/2855883/0/en/Corbus-Announces-Dosing-of-First-Patient-in-U-S-Phase-1-Clinical-Trial-of-Its-Next-Generation-Nectin-4-Targeting-ADC.html</id> <title type="text">Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC</title> <published>2024-04-02T12:00:00Z</published> <updated>2024-11-13T18:48:28Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/04/02/2855883/0/en/Corbus-Announces-Dosing-of-First-Patient-in-U-S-Phase-1-Clinical-Trial-of-Its-Next-Generation-Nectin-4-Targeting-ADC.html" /> <category term="Nasdaq:CRBP" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US21833P3010" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p>NORWOOD, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, announced today the first patient in the U.S. has been dosed in the Phase 1 clinical trial of CRB-701 (SYS6002), a next-generation antibody-drug-conjugate (ADC) targeting Nectin-4.</p>]]></content> <dc:identifier>2855883</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Corbus Pharmaceuticals Holdings, Inc.</dc:contributor> <dc:modified>Tue, 02 Apr 2024 12:00 GMT</dc:modified> <dc:subject>Health</dc:subject> <dc:subject>Clinical Study</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/03/12/2844478/0/en/Corbus-Pharmaceuticals-Reports-Fourth-Quarter-and-Year-End-2023-Financial-Results-and-Provides-Corporate-Update.html</id> <title type="text">Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update</title> <published>2024-03-12T12:00:00Z</published> <updated>2024-11-13T18:48:28Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/03/12/2844478/0/en/Corbus-Pharmaceuticals-Reports-Fourth-Quarter-and-Year-End-2023-Financial-Results-and-Provides-Corporate-Update.html" /> <category term="Nasdaq:CRBP" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US21833P3010" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">NORWOOD, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today provided a corporate update and reported financial results for the fourth quarter of 2023 and year-ended 2023.</p>]]></content> <dc:identifier>2844478</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Corbus Pharmaceuticals Holdings, Inc.</dc:contributor> <dc:modified>Tue, 12 Mar 2024 12:00 GMT</dc:modified> <dc:subject>Earnings Releases and Operating Results</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/03/06/2841358/0/en/Corbus-Pharmaceuticals-to-Participate-in-the-BMO-Capital-Markets-Inaugural-Obesity-Summit.html</id> <title type="text">Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit</title> <published>2024-03-06T13:00:00Z</published> <updated>2024-11-13T18:48:28Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/03/06/2841358/0/en/Corbus-Pharmaceuticals-to-Participate-in-the-BMO-Capital-Markets-Inaugural-Obesity-Summit.html" /> <category term="Nasdaq:CRBP" scheme="https://www.globenewswire.com/rss/stock" /> <category term="US21833P3010" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">NORWOOD, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a panel discussion at BMO Capital Markets <em>Inaugural</em> <em>BMO Obesity Summit </em>to be held on March 20, 2024 in New York City, NY.<br></p>]]></content> <dc:identifier>2841358</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Corbus Pharmaceuticals Holdings, Inc.</dc:contributor> <dc:modified>Wed, 06 Mar 2024 13:00 GMT</dc:modified> <dc:subject>Calendar of Events</dc:subject> </entry> </feed>